Clinical trials: Secondary Progressive Multiple Sclerosis (SPMS)
Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis
Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis
To assess the safety and of a single dose of IV infusion of placenta derived Mesenchymal Stem Cells (PLMSCs) in patients with secondary progressive Multiple Sclerosis (SPMS) disease.
- Conditions
- Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Mesenchymal Stem Cells
- Trial name
- MS (NCT06360861)
- Testing
- Allogenic placenta derived mesenchymal stem cells
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Tehran University of Medical Sciences
Secondary Progressive Multiple Sclerosis (SPMS)
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
- Trial name
- NCT04593927
- Testing
- Mayzent
- Where
- 174 sites in Japan
- Volunteers
- 451 people
- Sponsor
- Novartis Pharmaceuticals